NASDAQ:XBIO - Xenetic Biosciences Stock Price, News & Analysis

$1.84
-0.08 (-4.17 %)
(As of 08/20/2019 04:00 PM ET)
Today's Range
$1.78
Now: $1.84
$1.8902
50-Day Range
$1.61
MA: $5.51
$13.50
52-Week Range
$1.54
Now: $1.84
$54.60
Volume122,989 shs
Average Volume530,905 shs
Market Capitalization$1.60 million
P/E RatioN/A
Dividend YieldN/A
Beta2.55
Xenetic Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, research, and development of next-generation biologic drugs and novel orphan oncology therapeutics. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XBIO
CUSIPN/A
CIKN/A
Phone781-778-7720

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.59 million
Book Value$12.65 per share

Profitability

Net Income$-7,300,000.00

Miscellaneous

EmployeesN/A
Market Cap$1.60 million
Next Earnings Date11/8/2019 (Estimated)
OptionableNot Optionable

Receive XBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter.


Xenetic Biosciences (NASDAQ:XBIO) Frequently Asked Questions

What is Xenetic Biosciences' stock symbol?

Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO."

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences Inc (NASDAQ:XBIO) released its quarterly earnings data on Wednesday, November, 15th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.03. The firm earned $0.09 million during the quarter. View Xenetic Biosciences' Earnings History.

When is Xenetic Biosciences' next earnings date?

Xenetic Biosciences is scheduled to release their next quarterly earnings announcement on Friday, November 8th 2019. View Earnings Estimates for Xenetic Biosciences.

Has Xenetic Biosciences been receiving favorable news coverage?

Press coverage about XBIO stock has been trending positive recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Xenetic Biosciences earned a news impact score of 2.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for Xenetic Biosciences.

Are investors shorting Xenetic Biosciences?

Xenetic Biosciences saw a increase in short interest in July. As of July 31st, there was short interest totalling 213,400 shares, an increase of 256.9% from the June 30th total of 59,800 shares. Based on an average daily volume of 212,900 shares, the days-to-cover ratio is currently 1.0 days. Currently, 6.3% of the company's stock are short sold. View Xenetic Biosciences' Current Options Chain.

Who are some of Xenetic Biosciences' key competitors?

What other stocks do shareholders of Xenetic Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include Sorrento Therapeutics (SRNE), Veru (VERU), Opko Health (OPK), Tetraphase Pharmaceuticals (TTPH), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX), Viewray (VRAY), Zynerba Pharmaceuticals (ZYNE), Weatherford International (WFT) and Senseonics (SENS).

Who are Xenetic Biosciences' key executives?

Xenetic Biosciences' management team includes the folowing people:
  • Mr. Jeffrey F. Eisenberg, CEO, Pres & Director (Age 53)
  • Mr. James F. Parslow, CFO, COO & Corp. Sec. (Age 54)
  • Dr. Curtis A. Lockshin, Chief Scientific Officer (Age 59)

Who are Xenetic Biosciences' major shareholders?

Xenetic Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Morgan Stanley (4.14%) and Royal Bank of Canada (3.10%).

Which institutional investors are selling Xenetic Biosciences stock?

XBIO stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada.

Which institutional investors are buying Xenetic Biosciences stock?

XBIO stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley.

How do I buy shares of Xenetic Biosciences?

Shares of XBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Xenetic Biosciences' stock price today?

One share of XBIO stock can currently be purchased for approximately $1.84.

How big of a company is Xenetic Biosciences?

Xenetic Biosciences has a market capitalization of $1.60 million and generates $7.59 million in revenue each year. View Additional Information About Xenetic Biosciences.

What is Xenetic Biosciences' official website?

The official website for Xenetic Biosciences is http://www.xeneticbio.com/.

How can I contact Xenetic Biosciences?

Xenetic Biosciences' mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The company can be reached via phone at 781-778-7720 or via email at [email protected]


MarketBeat Community Rating for Xenetic Biosciences (NASDAQ XBIO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  124 (Vote Outperform)
Underperform Votes:  109 (Vote Underperform)
Total Votes:  233
MarketBeat's community ratings are surveys of what our community members think about Xenetic Biosciences and other stocks. Vote "Outperform" if you believe XBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel